11月21日 - ** 药物开发商Esperion ESPR.O股价盘前上涨1.7%，至3美元
** 公司称，在其日本合作伙伴大冢制药公司在日本推出降胆固醇药物Nexletol后，公司将获得9000万美元的付款。
** ESPR表示，大冢制药已获得国家批准，可以销售用于治疗高胆固醇和某些遗传性胆固醇疾病患者的Nexletol。
** ESPR 有资格获得额外的里程碑和日本销售额 15%-30%的特许权使用费
** ESPR表示，日本是心血管预防领域的第三大市场
** 截至上次收盘，股价年累计上涨约 34
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.